Literature DB >> 24963570

Prophylaxis against venous thromboembolism in ambulatory patients with cancer.

Jean M Connors1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24963570     DOI： 10.1056/NEJMra1401468

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  Venous thromboembolism in hematopoietic stem cell transplant recipients.

Authors:  S Chaturvedi; A Neff; A Nagler; U Savani; M Mohty; B N Savani
Journal:  Bone Marrow Transplant       Date:  2015-12-21       Impact factor: 5.483

2.  Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Authors:  J Haltout; A Awada; M Paesmans; M Moreau; J Klastersky; G Machiels; M Ignatiadis; N Kotecki
Journal:  Support Care Cancer       Date:  2019-01-04       Impact factor: 3.603

Review 3.  Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?

Authors:  Hikmat Abdel-Razeq; Asem Mansour
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

4.  Risk Factors of a Pulmonary Thromboembolism After Colorectal Surgery.

Authors:  Junyub Kim; Byung-Noe Bae; Hyun Seok Jung; Inseok Park; Hyunjin Cho; Geumhee Gwak; Kiwhan Kim; Hong-Joo Kim; Young Duk Kim
Journal:  Ann Coloproctol       Date:  2015-10-31

5.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Authors:  Anne Ws Rutjes; Ettore Porreca; Matteo Candeloro; Emanuele Valeriani; Marcello Di Nisio
Journal:  Cochrane Database Syst Rev       Date:  2020-12-18

Review 6.  Silent pulmonary thromboembolism in neurosurgery patients: Report of 2 cases and literature review.

Authors:  Rui Tian; Jun Gao; Alof Chen; Xinjie Bao; Jian Guan; Ming Feng; Yongning Li; Wenbin Ma; Zuyuan Ren; Renzhi Wang; Junji Wei
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

7.  Predictors of Venous Thromboembolism in Patients With Testicular Germ Cell Tumors: A Retrospective Study.

Authors:  Hikmat Abdel-Razeq; Faris Tamimi; Rashid Abdel-Razeq; Samer Salah; Zaid Omari; Osama Salama; Alaa Abufara; Abdalla Al-Tell; Hanna Qahoush; Ahmad Nasman; Ayat Taqash; Yazan Alhalaseh; Rayan Bater
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

8.  Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.

Authors:  Daniel Bastian Pfankuchen; Fabian Baltes; Tahira Batool; Jin-Ping Li; Martin Schlesinger; Gerd Bendas
Journal:  Oncotarget       Date:  2017-06-28

9.  Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial.

Authors:  Alok A Khorana; Mairéad G McNamara; Ajay K Kakkar; Michael B Streiff; Hanno Riess; Ujjwala Vijapurkar; Simrati Kaul; Peter Wildgoose; Gerald A Soff
Journal:  TH Open       Date:  2020-05-23

10.  The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.

Authors:  Lukas Maria Gockel; Jan Moritz Ponert; Svenja Schwarz; Martin Schlesinger; Gerd Bendas
Journal:  Molecules       Date:  2018-10-24       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.